Comparative analysis of fat and muscle proteins in fenofibrate-fed type II diabetic OLETF rats: The fenofibrate-dependent expression of PEBP or C11orf59 protein

BMB Reports

Volumn 43, Issue 5, 2010, Pages 337-343

  Hahm, Jong Ryeal ^a   Ahn, Jin Sook ^a   Noh, Hae Sook ^a   Baek, Seon Mi ^a   Ha, Ji Hye ^a   Jung, Tae Sik ^a   An, Yong Jun ^b   Kim, Duk Kyu ^b   Kim, Deok Ryong ^a  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Dong A University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; RATTUS;

EID: 77953507944     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2010.43.5.337     Document Type: Article

References (31)

1. Carey, D. G., Cowin, G. J., Galloway, G. J., Jones, N. P., Richards, J. C., Biswas, N. and Doddrell, D. M. (2002) Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes. Res, 10, 1008-1015.
2. Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E. and Fruchart, J. C. (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088-2093.
3. Kelly, D. E., Goodpaster, B., Wing, R. R. and Simoneau, J. A. (1999) Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am. J. Physiol. 277, 1130-1141.
4. Lee, H. J., Choi, S. S., Park, M. K., An, Y. J., Seo, S. Y., Kim, M. C., Hong, S. H., Hwang, T. H., Kang, D. Y., Garber, A. J. and Kim, D. K. (2002) Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem. Biophys. Res. Commun. 296, 293-299.
5. Koh, E. H., Kim, M. S., Park, J. Y., Kim, H. S., Youn, J. Y., Park, H. S., Youn, J. H. and Lee, K. U. (2003) Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 52, 2331-2337.
6. Lee, H. J., Park, M. K., Lee, K. I., An, Y. J., Kim, J. M., Park, J. Y., Han, Y, Hong, S. H., Choi, S. S., Yoo, Y. H., Suh, J. D. and Kim, D. K. (2007) Prevention of diabetes by fenofibrate in OLETF rats: hepatic mechanism for reducing visceral adiposity. J. Korean Diabetes Assoc. 31, 63-74.
7. Ye, J. M., Doyle, P. J., Iglesias, M. A., Watson, D. G., Cooney, G. J. and Kraegen, E. W. (2001) Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fatfed rats: comparison with PPAR-gamma activation. Diabetes 50, 411-417.
8. Guerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J. M., Winegar, D. A., Willson, T. M., Fruchart, J. C., Berge, R. K. and Staels, B. (2000) Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275, 16638-16642.
9. Zambon, A. and Cusi, K. (2007) The role of fenofibrate in clinical practice. Diabetes Vasc. Dis. Res. 4, 15-20.
10. Srivastava, R. A., Jahagirdar, R., Azhar, S., Sharma, S. and Bisgaier, C. L. (2006) Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol. Cell. Biochem. 285, 35-50.
11. Seo, Y. S., Kim, J. H., Jo, N. Y., Choi, K. M., Baik, S. H., Park, J. J., Kim, J. S., Byun, K. S., Bak, Y. T., Lee, C. H., Kim, A. and Yeon, J. E. (2008) PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J. Gastroenterol. Hepatol. 23, 102-109.
12. Hogue, J. C., Lamarche, B., Tremblay, A. J., Bergeron, J., Gagné, C. and Couture, P. (2008) Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 57, 380-386.
13. Aasum, E., Khalid, A. M., Gudbrandsen, O. A., How, O. J., Berge, R. K. and Larsen, T. S. (2008) Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J. Mol. Cell. Cardiol. 44, 201-209.
14. Zhao, Z., Lee, Y. J., Kim, S. K., Kim, H. J., Shim, W. S., Ahn, C. W., Lee, H. C., Cha, B. S. and Ma, Z. A. (2009) Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle. Life Sci. 84, 688-695.
15. Park, C. W., Zhang, Y., Zhang, X., Wu, J., Chen, L., Cha, D. R., Su, D., Hwang, M. T., Fan, X., Davis, L., Striker, G., Zheng, F., Breyer, M. and Guan, Y. (2006) PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 69, 1511-1517.
16. Chen, Y. J. and Quilley, J. (2008) Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release. J. Pharmacol. Exp. Ther. 324, 658-663.
17. Park, M. K., Lee, H. J., Hong, S. H., Choi, S. S., Yoo, Y. H., Lee, K. I. and Kim, D. K. (2007) The increase in hepatic uncoupling by fenofibrate contributes to a decrease in adipose tissue in obese rats. J. Korean Med. Sci. 22, 235-241.
18. Zawalich, W. and Zawalich, K. (1985) Effect of exogenous phospholipase A2 on insulin secretion from perifused rat islets. Diabetes 34, 471-476.
19. Ramanadham, S., Ma, Z., Arita, H., Zhang, S. and Turk, J. (1998) Type IB secretory phospholipase A2 is contained in insulin secretory granules of pancreatic islet beta-cells and is co-secreted with insulin from glucose-stimulated islets. Biochim. Biophys. Acta. 1390, 301-312.
20. Fryirs, M., Barter, P. J. and Rye, K. A. (2009) Cholesterol metabolism and pancreatic beta-cell function. Curr. Opin. Lipidol. 20, 159-164.
21. Hofer-Warbinek, R., Schmid, J. A., Mayer, H., Winsauer, G., Orel, L., Mueller, B., Wiesner, C. H., Binder, B. R. and de Martin, R. A. (2004) Highly conserved proapoptotic gene, IKIP, located next to the APAF1 gene locus, is regulated by p53. Cell Death Differ. 11, 1317-1325.
22. Ruan, H. and Pownall, H. J. (2009) The adipocyte IKK/NFkappaB pathway: a therapeutic target for insulin resistance. Curr. Opin. Investig. Drugs 10, 346-352.
23. Lappas, M., Yee, K., Permezel, M. and Rice, G. E. (2005) Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-kappa B and I kappa B kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology 146, 1491-1497.
24. Karlberg, N., Jalanko, H., Kallijärvi, J., Lehesjoki, A. E. and Lipsanen-Nyman, M. (2005) Insulin resistance syndrome in subjects with mutated RING finger protein TRIM37. Diabetes 54, 3577-3581.
25. Yeung, K., Seitz, T., Li,S., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D. W., Mischak, H., Sedivy, J. M. and Kolch, W. (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401, 173-177.
26. Jager, J., Grémeaux, T., Gonzalez, T., Bonnafous, S., Debard, C., Laville, M., Vidal, H., Tran, A., Gual, P., Le Marchand-Brustel, Y., Cormont, M. and Tanti, J. F. (2010) Tpl2 kinase is up-regulated in adipose tissue in obesity and may mediate IL-1{beta} and TNF-{alpha} effects on ERK activation and lipolysis. Diabetes 59, 61-70.
27. Izawa, Y., Yoshizumi, M., Fujita, Y., Ali, N., Kanematsu, Y., Ishizawa, K., Tsuchiya, K., Obata, T., Ebina, Y., Tomita, S. and Tamaki, T. (2005) ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. Exp. Cell Res. 308, 291-299.
28. Zheng, Y., Zhang, W., Pendleton, E., Leng, S., Wu, J., Chen, R. and Sun, X. J. (2009) Improved insulin sensitivity by calorie restriction is associated with reduction of ERK and p70S6K activities in the liver of obese Zucker rats. J. Endocrinol. 203, 337-347.
29. Kanda, T., Wakino, S., Homma, K., Yoshioka, K., Tatematsu, S., Hasegawa, K., Takamatsu, I., Sugano, N., Hayashi, K. and Saruta, T. (2006) Rho-kinase as a molecular target for insulin resistance and hypertension. FASEB J. 20, 169-171.
30. Baek, S. M., Ahn, J. S., Noh, H. S., Park, J., Kang, S. S. and Kim, D. R. (2010) Proteomic analysis in NSAIDs-treated primary cardiomyocytes. J. Proteomics 73, 721-732.
31. Kim, D. R. (2001) Determination of monoclonal antibodies capable of recognizing the native protein using surface Plasmon resonance. J. Biochem. Mol. Biol. 34, 452-456.